SHR 7390Alternative Names: SHR-7390
Latest Information Update: 22 Nov 2016
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Nov 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (In adults; In the elderly; Late-stage disease; Metastatic disease) in China (NCT02968485)
- 07 Oct 2016 Preclinical trials in Solid tumours in China (PO) before October 2016 (NCT02968485)